Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Recent research has provided scientific validation for the use of certain bacteria—specifically, probiotics and commensal skin bacteria—to support the treatment of eczema (atopic dermatitis). Eczema is characterized by inflammation, skin barrier dysfunction, and an imbalance in the skin microbiome, often involving an overgrowth of Staphylococcus aureus. Several studies have shown that oral administration of specific probiotic strains (such as Lactobacillus rhamnosus GG, Lactobacillus fermentum, and Bifidobacterium species) can modestly reduce the severity of eczema symptoms, particularly in children. The proposed mechanisms include modulation of immune responses and restoration of microbial balance. In addition, emerging topical treatments use beneficial skin bacteria, such as Roseomonas mucosa or Staphylococcus hominis, to outcompete pathogenic microbes and restore a healthy skin environment. Early-phase clinical trials have shown potential improvements in eczema severity with such approaches. However, the overall quality of evidence is moderate, with some studies reporting benefit and others showing limited or no effect. There is not yet a clear consensus on which bacterial strains are most effective, optimal dosages, or long-term safety. Therefore, while the use of bacteria in supporting eczema treatment is grounded in scientific research and holds promise, further well-designed clinical trials are needed to establish definitive recommendations.

More about Bacteria
More about Eczema

Other ingredients used for Eczema

Other health conditions supported by Bacteria

Products containing Bacteria